MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vertex Pharmaceuticals Inc

Închisă

SectorSănătate

483.28 -0.22

Rezumat

Modificarea prețului

24h

Curent

Minim

479.62

Maxim

487.51

Indicatori cheie

By Trading Economics

Venit

-132M

913M

Vânzări

142M

2.9B

P/E

Medie Sector

30.42

63.778

EPS

3.98

Marjă de profit

31.353

Angajați

6,100

EBITDA

-99M

1.2B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+2.96% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

6.8B

127B

Deschiderea anterioară

483.5

Închiderea anterioară

483.28

Sentimentul știrilor

By Acuity

12%

88%

14 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 feb. 2025, 22:11 UTC

Câștiguri

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 ian. 2025, 00:19 UTC

Principalele dinamici ale pieței

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 dec. 2024, 12:25 UTC

Principalele dinamici ale pieței

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 nov. 2024, 21:44 UTC

Câștiguri

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1 aug. 2024, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb. 2025, 21:12 UTC

Câștiguri

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 feb. 2025, 14:21 UTC

Câștiguri

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 feb. 2025, 21:12 UTC

Câștiguri

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 feb. 2025, 21:12 UTC

Câștiguri

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 feb. 2025, 21:11 UTC

Câștiguri

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 feb. 2025, 21:04 UTC

Câștiguri

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 feb. 2025, 21:04 UTC

Câștiguri

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 feb. 2025, 21:02 UTC

Câștiguri

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 feb. 2025, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 feb. 2025, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 feb. 2025, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 feb. 2025, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 ian. 2025, 09:59 UTC

Acțiuni populare

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 nov. 2024, 22:21 UTC

Câștiguri

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 nov. 2024, 21:25 UTC

Câștiguri

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 nov. 2024, 21:03 UTC

Câștiguri

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4 nov. 2024, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4 nov. 2024, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4 nov. 2024, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26 sept. 2024, 14:20 UTC

Achiziții, Fuziuni, Preluări

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1 aug. 2024, 20:30 UTC

Câștiguri

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 aug. 2024, 20:03 UTC

Câștiguri

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 aug. 2024, 20:02 UTC

Câștiguri

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 aug. 2024, 20:02 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Comparație

Modificare preț

Vertex Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

2.96% sus

Prognoză pe 12 luni

Medie 499.09 USD  2.96%

Maxim 591 USD

Minim 320 USD

În baza a 27 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVertex Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

27 ratings

16

Cumpărare

10

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

480.95 / 505Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

14 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.